Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel for Dysphoric Hypomania in Bipolar II Patients
NCT00186043Phase 4Completed
- Sponsor
- Stanford University
- Start
- Aug 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of quetiapine in Bipolar II disorder (BP-II), sponsored by Stanford University. Primary endpoint: Clinical Global Impression for Bipolar Disorders Overall Severity Response at 8 weeks. Started Aug 2008; status: completed.
02
Drugs
quetiapine
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT00186043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186043.